ba 1

Potent bombesin receptor agonist (IC50 values are 0.26, 1.55 and 2.52 nM for BB1, BB2 and BB3 respectively). Enhances glucose transport in obese and diabetic primary myocytes. Also stimulates NCI-H1299 lung cancer cell proliferation in vitro.

BA 1 TFA acts as a potent agonist for the bombesin (BB) family of receptors, exhibiting high affinity binding to Bombesin receptor subtype-3 (BRS3), gastrin-releasing peptide receptor (GRPR), and neuromedin B receptor (NMBR), with IC50 values of 6, 0.4, and 2.5 nM, respectively [1].

BA 1 acetate is a potent bombesin receptor agonist (IC50 values are 0.26, 1.55 and 2.52 nM for BB1, BB2 and BB3 respectively). Enhances glucose transport in obese and diabetic primary myocytes. Also stimulates NCI-H1299 lung cancer cell proliferation in v

BA-AZT1 acts as an inhibitor of HBV polymerase (HBV polymerase) and sodium taurocholate cotransporting polypeptide (NTCP). It hinders the secretion of viral capsid proteins HBsAg and HBeAg, with IC50 values of 0.65 µM and 13.42 µM, respectively, and inhibits HBV DNA replication with an IC50 of 0.70 µM.

Balanol is an ATP-competitive Protein Kinase C and Protein Kinase A inhibitor.

Propanidid (Sombrevin) is a gamma-aminobutyric acid type A receptor (GABAA) agonist and a fast-acting intravenous anesthetic that lowers arterial blood pressure.

SMBA1 is a highly potent Bax agonist with antitumor activity that induces cell cycle arrest and apoptosis in malignant glioma cells. SMBA1 can be used to study triple-negative breast cancer.

Aminoglutethimide (BA-16038), an aromatase inhibitor, is used in the therapy of advanced BREAST Y.

Mefruside is an orally effective diuretic that reduces tubular reabsorption of electrolytes and water, suitable for studying edema and hypertension. It inhibits urea synthesis in an in vitro rat liver perfusion model.

Lotilaner is a parasiticide. It is used as a potent non-competitive antagonist of insects GABACl receptors (IC50 of 23.84 nM for Drosophila melanogaster GABA receptor). It also has no effect on a dog GABAA receptor.

Phenglutarimid is an anticholinergic. It is used as an antiparkinsonian agent.

PYZD-4409 is a selective UBA1 inhibitor with an IC50 of 20 μM. PYZD-4409 induces cell death in malignant cells and is preferentially cytotoxic to malignant cells over normal hematopoietic cells.

TAK-243 (MLN7243) is a selective inhibitor of the ubiquitin-activating enzyme UAE (IC50=1 nM), blocking ubiquitin binding and disrupting both mono-ubiquitin signaling and overall protein ubiquitination. TAK-243 exhibits antitumor activity and promotes apoptosis.

Thiambutosine exhibits inhibitory activity against Mycobacterium leprae and mushroom tyrosinase, making it suitable for infection studies.

PBA-1105 TFA is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. This compound selectively binds to the exposed hydrophobic regions of misfolded proteins, promoting their degradation through the autophagy (autophagy) pathway. Additionally, PBA-1105 TFA enhances the autophagic flux of Ub-bound aggregates.

Silagaba132 is a silicon-containing GABA derivative which treats neuropathic pain without central nervous system related side effects.

Silagaba161 is a silicon-containing GABA derivative which treats neuropathic pain without central nervous system related side effects.

ISRIB-A15 (ISR-IN-2) is an potent inhibitor of the integrated stress response with an EC50 of 0.8 nM.

trans-isrib A17 (ISR-IN-1) is an potent inhibitor of the integrated stress response with EC50 of 0.6 nM.

MEN91507 is a new CysLT(1) receptor antagonist.

BA-1049 is a selective ROCK2 inhibitor.

SABA1 exhibits antibacterial activity, inhibiting Pseudomonas aeruginosa and Escherichia coli, and suppresses biotin carboxylase, making it useful for studying biological resistance.

Ociperlimab (BGB-A1217) is a humanized antibody targeting TIGIT with antitumor activity. It blocks the TIGIT-PVR interaction and is used in the study of advanced solid tumors.

Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD).